{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:30Z","timestamp":1789133130630,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"1.3.5 Project of High Altitude Medicine","award":["No. GYYX24003"],"award-info":[{"award-number":["No. GYYX24003"]}]},{"name":"West China Hospital, Sichuan University, and National Natural Science Foundation of China","award":["82370192"],"award-info":[{"award-number":["82370192"]}]},{"name":"West China Hospital, Sichuan University, and National Natural Science Foundation of China","award":["U24A20680"],"award-info":[{"award-number":["U24A20680"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Invasive fungal disease (IFD) remains a life-threatening complication in patients with hematological diseases. Isavuconazole was approved by the FDA for primary treatment of invasive aspergillosis and mucormycosis. While clinical trials have demonstrated its efficacy, data on its use in hematology patients remain limited. This study aims to evaluate the real-world effectiveness and safety of isavuconazole in this population. We conducted a single-center, retrospective study of hematology patients who received isavuconazole for IFD between 1 June 2022, and 31 July 2024, at West China Hospital, Sichuan University. A total of 66 patients with proven (n = 9), probable (n = 17), or possible (n = 40) IFD were included in the study. Acute leukemia (AL) was the most common underlying disease, affecting 27 patients (40.9%), followed by non-Hodgkin\u2019s lymphoma (NHL) and myelodysplastic syndrome (MDS). Over 80.0% of patients received oral isavuconazole. At 6 weeks of follow-up, a favorable response was observed in 57.6% of patients, increasing to 71.2% at 12 weeks. Factors associated with achieving complete response in isavuconazole treatment included receiving isavuconazole as primary treatment (OR = 0.10, p = 0.01) and reaching complete\/partial remission (CR\/PR) of the primary hematological disease (OR = 0.07, p = 0.003). The all-cause mortality rates were under 30.0%. The use of isavuconazole as primary antifungal therapy (p &lt; 0.05) and achieving CR\/PR in the underlying hematological disease (p &lt; 0.05) were two independent predictors of improved clinical outcomes. Adverse events were reported in 33.3% of patients, and no adverse events led to discontinuation of treatment. Our study demonstrated that isavuconazole is an effective and well-tolerated treatment for IFD in hematology patients. The oral formulation provided comparable efficacy and enhanced compliance, potentially leading to improved outcomes and optimizing the management strategy. The generalizability of our findings may be limited by the single-center, retrospective nature; further validation through prospective, multi-center studies is needed.<\/jats:p>","DOI":"10.3390\/microorganisms13122677","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:50:20Z","timestamp":1764060620000},"page":"2677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isavuconazole for the Treatment of Invasive Fungal Disease in Hematology Patients: A Real-World Retrospective Study on Efficacy and Safety"],"prefix":"10.3390","volume":"13","author":[{"given":"Pazilaiti","family":"Tuohuti","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"West China School of Medicine, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6245-4619","authenticated-orcid":false,"given":"Yuhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"West China School of Medicine, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref_1","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: A multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.3324\/haematol.2016.151837","article-title":"Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study","volume":"102","author":"Tisi","year":"2017","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jmii.2018.01.002","article-title":"Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008\u20132013","volume":"53","author":"Chen","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3324\/haematol.2011.044636","article-title":"Invasive aspergillosis in patients with hematologic malignancies: Incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009","volume":"96","author":"Nicolle","year":"2011","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dagher, H., Hachem, R., Chaftari, A.M., Jiang, Y., Ali, S., Deeba, R., Shah, S., and Raad, I. (2022). Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant. J. Fungi, 8.","DOI":"10.3390\/jof8010074"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ellsworth, M., and Ostrosky-Zeichner, L. (2020). Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. J. Fungi, 6, Erratum in J. Fungi 2025, 11, 226. https:\/\/doi.org\/10.3390\/jof11030226.","DOI":"10.3390\/jof11030226"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","first-page":"79","article-title":"Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections","volume":"9","author":"Donnelley","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0043-1777259","article-title":"Aspergillus and the Lung","volume":"45","author":"Janssens","year":"2024","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Batista, M.V., Ussetti, M.P., Jiang, Y., Neofytos, D., Cortez, A.C., Feriani, D., Schmidt-Filho, J., Fran\u00e7a-Silva, I.L.A., Raad, I., and Hachem, R. (2023). Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study. J. Fungi, 9.","DOI":"10.3390\/jof9020166"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/12\/2677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:18:03Z","timestamp":1764062283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/12\/2677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["microorganisms13122677"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms13122677","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}